Spero Therapeutics, Inc. (SPRO) — 10-Q Filings
All 10-Q filings from Spero Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Spero Narrows Losses, Pivots to Tebipenem HBr Amid Program Cuts
— Nov 13, 2025 Risk: high
Spero Therapeutics, Inc. reported a net loss of $7.38 million for the three months ended September 30, 2025, a significant improvement from the $17.15 million n -
Spero's Q2 Loss Widens to $19.9M Amid R&D Shifts
— Aug 12, 2025 Risk: high
Spero Therapeutics, Inc. reported a net loss of $19.9 million for the three months ended June 30, 2025, a significant increase from the $10.1 million net loss i -
Spero Therapeutics Files Q1 2025 10-Q
— May 13, 2025 Risk: low
Spero Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company's business address is 675 Massachusetts Avenue, 14th Floor, Cambridge, M -
Spero Therapeutics Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Spero Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its busines -
Spero Therapeutics Files Q2 2024 10-Q
— Aug 5, 2024 Risk: medium
Spero Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the first six months of -
Spero Therapeutics Files 10-Q for Period Ending March 31, 2024
— May 15, 2024 Risk:
Spero Therapeutics, Inc. (SPRO) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Spero Therapeutics, Inc. filed a 10-Q report for the quarter ended
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX